Tecartus Disease Interactions
There is 1 disease interaction with Tecartus (brexucabtagene autoleucel).
Brexucabtagene autoleucel (applies to Tecartus) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Brexucabtagene autoleucel has caused severe or life-threatening infections, including hepatitis B reactivation and fatal opportunistic infections in immunosuppressed patients. Screening for hepatitis B and C virus, and for human immunodeficiency virus (HIV) in accordance with clinical guidelines should be performed before collection of cells for manufacturing. Monitor patients for signs and symptoms of infection before and after infusion, administer prophylactic antimicrobials as needed, and treat promptly and appropriately any infection.
References
- (2020) "Product Information. Tecartus (brexucabtagene autoleucel)." Kite Pharma, Inc.
Tecartus drug interactions
There are 200 drug interactions with Tecartus (brexucabtagene autoleucel).
More about Tecartus (brexucabtagene autoleucel)
- Tecartus consumer information
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.